Summary
Medtronic plc (MDT) announced on March 13, 2019, a change to its Board of Directors. The size of the Board has been expanded from 10 to 11 members with the appointment of Dr. Andrea Goldsmith, effective March 11, 2019. Dr. Goldsmith will serve until the upcoming 2019 Annual Meeting of Shareholders and is expected to be nominated for election by shareholders at that time. This appointment brings a new independent director to the Board, potentially offering fresh perspectives on strategic decisions and corporate governance. Investors can expect Dr. Goldsmith to be compensated according to Medtronic's established non-employee director compensation policy, which includes an annual cash retainer and an equity grant. The filing also confirms there are no undisclosed conflicts of interest or related-party transactions involving Dr. Goldsmith.
Key Highlights
- 1Board size increased from 10 to 11 directors.
- 2Dr. Andrea Goldsmith appointed as a new director, effective March 11, 2019.
- 3Dr. Goldsmith to serve until the 2019 Annual Meeting of Shareholders.
- 4She will be eligible for standard non-employee director compensation (cash retainer and equity grant).
- 5No disclosed arrangements or understandings led to her selection.
- 6No reportable related-party transactions involving Dr. Goldsmith.
- 7Appointment announced via press release dated March 14, 2019.